OraSure Technologies, Inc. (OSUR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

OraSure Technologies, Inc. (OSUR) Healthcare & Pipeline Overview

OraSure Technologies, Inc. specializes in oral fluid diagnostics and specimen collection devices, offering products like the InteliSwab COVID-19 rapid test and OraQuick HIV test. The company serves clinical laboratories, hospitals, and government agencies, positioning itself in the infectious disease and molecular solutions markets.

What Is the Investment Thesis for OSUR?

OraSure Technologies presents a mixed investment thesis. The company's established presence in the infectious disease testing market, particularly with its OraQuick HIV test, provides a stable revenue stream. The COVID-19 pandemic significantly boosted sales of its InteliSwab rapid tests, but future revenue sustainability is uncertain as the pandemic subsides. The company's expansion into molecular solutions and genomics offers long-term growth potential, but requires continued investment in research and development. OraSure's negative profit margin of -61.9% raises concerns about profitability and operational efficiency. Successful execution of its growth strategies and improved cost management are critical for long-term value creation. Investors should closely monitor the company's ability to diversify its revenue streams and achieve profitability.

Based on FMP financials and quantitative analysis

OSUR Key Highlights

Market Cap of $222M reflects its position as a smaller player in the diagnostics market.

• Gross Margin of 38.8% indicates the profitability of its products before operating expenses.
• Profit Margin of -61.9% highlights significant challenges in achieving overall profitability.
• Beta of 0.85 suggests lower volatility compared to the broader market.
• No dividend yield reflects a focus on reinvesting earnings for growth.

Who Are OSUR's Competitors?

OSUR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OSUR's Key Strengths?

Established brand recognition with OraQuick.

• Proprietary oral fluid collection technology.
• Diverse product portfolio in diagnostics and molecular solutions.
• Strong distribution network.

What Are OSUR's Weaknesses?

Negative profit margin.

• Dependence on COVID-19 testing revenue.
• Limited geographic presence in emerging markets.
• Intense competition in the diagnostics industry.

What Could Drive OSUR Stock Higher?

OSUR catalyst: Expansion of the Molecular Solutions segment with new product launches in genomics and microbiome research.

• Strategic partnerships to expand market reach in Asia-Pacific and Latin America.
• Development of new diagnostic tests for emerging infectious diseases.
• Regulatory approvals for new at-home diagnostic tests.

What Are the Key Risks for OSUR?

Negative return on equity (-14.7%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Declining demand for COVID-19 testing impacting revenue.
• Intense competition in the diagnostics industry.
• Regulatory changes and reimbursement policies affecting market access.
• Economic downturn impacting healthcare spending.
• Dependence on key suppliers for critical components.

What Are the Growth Opportunities for OSUR?

• Expansion in Molecular Solutions: OraSure's Molecular Solutions segment, featuring Oragene and ORAcollect products, offers significant growth potential in the genomics and microbiome research markets. The increasing demand for genetic testing in areas such as ancestry, disease risk management, and personalized medicine drives market growth. By expanding its product offerings and laboratory services, OraSure can capitalize on this trend. The global genomics market is projected to reach $55.8 billion by 2028, presenting a substantial opportunity for OraSure to increase its market share through strategic partnerships and product innovation.
• Geographic Expansion: OraSure has the opportunity to expand its geographic presence beyond the United States and Europe. Emerging markets in Asia-Pacific and Latin America offer significant growth potential due to increasing healthcare expenditure and rising awareness of diagnostic testing. By establishing distribution networks and partnerships in these regions, OraSure can tap into new customer segments and diversify its revenue streams. Tailoring its product offerings to meet the specific needs of these markets is crucial for successful expansion, with a focus on affordable and accessible diagnostic solutions.
• Strategic Partnerships and Acquisitions: OraSure can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other diagnostic companies or acquiring complementary technologies can enhance its competitive position and accelerate growth. For example, partnering with a company specializing in point-of-care diagnostics could strengthen its presence in the rapid testing market. Careful selection of partners and acquisition targets is essential to ensure strategic alignment and value creation, with a focus on synergies and complementary capabilities.
• Development of New Diagnostic Tests: OraSure can invest in the development of new diagnostic tests for emerging infectious diseases and other health conditions. By leveraging its expertise in oral fluid-based diagnostics, the company can create innovative testing solutions that address unmet needs in the market. For example, developing rapid tests for respiratory viruses or sexually transmitted infections could drive significant revenue growth. A focus on user-friendly and accurate testing solutions is crucial for gaining market acceptance and adoption, with a focus on ease of use and accessibility.
• Increased Adoption of At-Home Testing: The trend towards at-home testing is accelerating, driven by convenience and accessibility. OraSure can capitalize on this trend by expanding its portfolio of at-home diagnostic tests, such as the OraQuick In-Home HIV test. By offering convenient and discreet testing solutions, the company can reach new customer segments and increase its market share. Marketing and distribution strategies should focus on raising awareness of the benefits of at-home testing and ensuring easy access to its products through online channels and retail partnerships. The global at-home testing market is expected to grow significantly in the coming years, presenting a substantial opportunity for OraSure.

What Are OSUR's Competitive Advantages?

• Proprietary oral fluid collection technology.
• Established brand recognition with OraQuick HIV test.
• Strong relationships with key distributors and healthcare providers.
• Regulatory approvals for its diagnostic tests.
• Expertise in genomics and microbiome research.

What Does OSUR Do?

OraSure Technologies, Inc., founded in 2000 and headquartered in Bethlehem, Pennsylvania, is a global leader in the development, manufacture, and marketing of oral fluid diagnostic products and specimen collection devices. The company operates through two primary segments: Diagnostics and Molecular Solutions. The Diagnostics segment focuses on rapid tests for infectious diseases, including HIV, Hepatitis C, and Ebola, as well as substance abuse testing solutions. A key product in this segment is the OraQuick Rapid HIV test, known for its ease of use and rapid results. The Molecular Solutions segment provides products and services for genomics and microbiome research, including Oragene and ORAcollect collection kits, and GenoFIND genomics laboratory services. These products are used to collect, stabilize, transport, and store samples of genetic material for various applications, such as ancestry testing, disease risk management, and lifestyle analysis. OraSure's products are marketed to a diverse customer base, including clinical laboratories, hospitals, clinics, community-based organizations, government agencies, and commercial entities across the United States, Europe, and internationally. The company's portfolio also includes the InteliSwab COVID-19 rapid test, which gained prominence during the COVID-19 pandemic, and the Colli-Pee collection device for urine collection. OraSure continues to innovate in the diagnostic and molecular testing space, focusing on expanding its product offerings and reaching new markets.

What Products and Services Does OSUR Offer?

• Develops and manufactures oral fluid diagnostic products.
• Offers rapid tests for infectious diseases like HIV, Hepatitis C, and Ebola.
• Provides specimen collection devices for genomics and microbiome research.
• Markets its products to clinical laboratories, hospitals, and government agencies.
• Offers at-home testing solutions for HIV and other conditions.
• Provides genomic products under the Oragene and ORAcollect brands.
• Offers GenoFIND genomics laboratory services.
• Develops and sells kits for collecting, stabilizing, and transporting genetic material.

How Does OSUR Make Money?

• Sales of diagnostic tests and specimen collection devices.
• Revenue from genomic laboratory services.
• Distribution agreements with healthcare providers and distributors.
• Government contracts for public health initiatives.

What Industry Does OSUR Operate In?

OraSure Technologies operates within the medical instruments and supplies industry, which is characterized by continuous innovation and evolving regulatory landscapes. The market for diagnostic testing is driven by increasing healthcare expenditure, rising prevalence of infectious diseases, and growing demand for personalized medicine. Competition is intense, with established players and emerging companies vying for market share. OraSure's focus on oral fluid-based diagnostics provides a unique niche, but the company faces competition from traditional blood-based testing methods and point-of-care diagnostics. The industry is also subject to stringent regulatory requirements and reimbursement policies, which can impact market access and profitability.

Who Are OSUR's Key Customers?

• Clinical laboratories.
• Hospitals and clinics.
• Community-based organizations.
• Government agencies.
• Commercial and industrial entities.

Over the past six months, OraSure Technologies, Inc. insiders filed 18 SEC Form 4 transactions — 4 sales and 14 purchases. On net that is roughly 385K shares acquired (about $223K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: OraSure Technologies, Inc.

Revenue for OraSure Technologies, Inc. came in at $30.6M during Q2 FY2026, a 9.7% improvement versus the preceding quarter. The company recorded net income of $6.2M, with diluted EPS of $0.09. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, OSUR averaged $-0.17 in diluted EPS.

OSUR Valuation & Market Position

With a $222M market cap, OraSure Technologies, Inc. sits in the micro-cap segment of the market. Relative to its peer group, OSUR's quantitative score of 31/100 is below the peer average of 65/100.

Return on equity for OraSure Technologies, Inc. stands at -14.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -19.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -19.8%, the inverse of the P/E and a quick read on earnings relative to price.

OraSure Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.01 places it in the safe zone, indicating low near-term bankruptcy risk.

OraSure Technologies, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 33.8% below estimates on average.

Company Profile

OraSure Technologies, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Bethlehem, US. The company is led by CEO Carrie Eglinton Manner. OSUR has traded publicly since 1986.

OSUR Financials

OSUR Latest News

OSUR Analyst Consensus

OSUR MoonshotScore

OraSure Technologies, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources